Serum and imaging biomarkers

Ingrid H.E. Korenromp, Lisa A. Maier, Jan C. Grutters*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Over the last 10 years, a range of biomarkers have been evaluated in sarcoidosis. Based on extensive literature reviews over this period, the single serum analytes serum ACE, soluble IL-2 receptor and chitotriosidase stand out as potential diagnostic and monitoring tools with significant sensitivity and specificity, although none functions alone as a gold standard biomarker. Other proteins, such as YKL-40, Krebs von den Lungen-6, cathepsin S and IFN-γ-induced protein 10, show potential as biomarkers. Unfortunately, data on serum biomarkers for use as a prognostic tool (to predict disease outcome, irrespective of treatment) or as a predictive tool (to predict the effect of therapy) are scarce. With respect to imaging modalities as biomarkers,18F-FDG PET seems to have potential as a prognostic tool. This nuclear biomarker may also help in determining treatable inflammatory lesions in symptomatic patients with indecisive conventional tests. Future research on biomarkers, including those emerging from novel technologies, as well as the utility of combined biomarkers, should rely on carefully designed prospective trials to allow translation and implementation in routine clinical care.

Original languageEnglish
Pages (from-to)107-121
Number of pages15
JournalERS Monograph
Issue number96
Publication statusPublished - 2022


Dive into the research topics of 'Serum and imaging biomarkers'. Together they form a unique fingerprint.

Cite this